News AZ's Truqap and Roche assay cleared for PTEN prostate cancer AstraZeneca has claimed a second approval for AKT inhibitor Truqap, in prostate cancer, that should help achieve its blockbuster hopes for the drug.
Oncology After Pluvicto: Alpha radiopharma and prostate cancer Dr Philip Kantoff, a world-renowned prostate cancer clinician and researcher, discusses alpha radiopharma treatment possibilities.
Oncology ASCO 26: Precision medicine takes a village, with Carolyn So... In this interview with pharmaphorum, J&J's Henar Hevia and Carolyn Sousa, share their some of the company's data wins at the show and talk trends.
News ASCO26: Big win for Erleada in perioperative prostate cancer ASCO today brings good news for patients with localised prostate cancer, as early use of J&J's ARPI offers a 19 month increase in median survival.
News Review advises against broad NHS prostate cancer screening The UK's National Screening Committee has concluded that the harms of widespread prostate cancer screening would outweigh its benefits.
News Obesity biotech Kalohexis files confidential IPO Just weeks after forming as a spinout from Endevica Bio, obesity drug developer Kalohexis has filed for an IPO.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
